Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $215.67 USD
Change Today -2.42 / -1.11%
Volume 878.6K
GEVA On Other Exchanges
As of 8:10 PM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

synageva biopharma corp (GEVA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/2/15 - $219.30
52 Week Low
09/22/14 - $60.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

synageva biopharma corp (GEVA) Related Bloomberg News

View More Bloomberg News

synageva biopharma corp (GEVA) Related Businessweek News

No Related Businessweek News Found

synageva biopharma corp (GEVA) Details

Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company’s lead program include sebelipase alfa, a recombinant form of human lysosomal acid lipase (LAL) under the Kanuma brand name for the treatment of LAL deficiency in infants, children, and adults. It also has various other research programs in various stages of preclinical development, including SBC-103, an enzyme replacement therapy in a Phase 1/2 study for lysosomal storage disease, known as mucopolysaccharidosis type IIIB; SBC-105, an enzyme replacement therapy in preclinical development for rare disorders of calcification; and other programs. The company was founded in 1996 and is headquartered in Lexington, Massachusetts.

282 Employees
Last Reported Date: 02/26/15
Founded in 1996

synageva biopharma corp (GEVA) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $631.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $374.9K
Chief Operating Officer
Total Annual Compensation: $210.8K
Chief Medical Officer, Head of Research & Dev...
Total Annual Compensation: $406.7K
Executive Vice President of Global Medical an...
Total Annual Compensation: $379.6K
Compensation as of Fiscal Year 2014.

synageva biopharma corp (GEVA) Key Developments

Synageva BioPharma Submits Kanuma™ (Sebelipase Alfa) Application For LAL Deficiency In Japan

Synageva BioPharma Corp. announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare in Japan for Kanuma™ (sebelipase alfa) as a treatment for patients with lysosomal acid lipase deficiency (LAL Deficiency). Upon approval, Kanuma would be the first approved therapy for these patients. The NDA for Kanuma included previously reported data from the global, randomized, double-blind, placebo controlled Phase 3 trial in children and adults with LAL Deficiency, which included enrollment of Japanese patients, and the Phase 2/3 trial of Kanuma in infants with LAL Deficiency. The MHLW previously granted Orphan Drug Designation (ODD) to sebelipase alfa for the treatment of patients with LAL Deficiency. As a result, this NDA will receive priority review for marketing authorization, and, if approved, sebelipase alfa would have 10 years of market exclusivity for the designated indication.

Alexion Pharmaceuticals, Inc., Synageva BioPharma Corp. - M&A Call

To discuss the acquisition transaction between Alexion Pharmaceuticals, Inc. and Synageva BioPharma Corp

Synageva BioPharma Corp. Proposes Amendment to Bylaws

Synageva BioPharma Corp. announced that it will propose amendment to company Bylaws to adopt a forum selection clause at the Annual Meeting of Stockholders to be held on June 26, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEVA:US $215.67 USD -2.42

GEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GEVA.
View Industry Companies

Industry Analysis


Industry Average

Valuation GEVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,364.5x
Price/Book 11.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,267.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNAGEVA BIOPHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at